Cara Therapeutics traded at $11.24 this Tuesday August 16th, decreasing $0.52 or 4.38 percent since the previous trading session. Looking back, over the last four weeks, Cara Therapeutics lost 22.39 percent. Over the last 12 months, its price fell by 11.67 percent. Looking ahead, we forecast Cara Therapeutics to be priced at 11.19 by the end of this quarter and at 10.27 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
11.28
Daily Change
-4.00%
Yearly
-11.32%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Chugai Pharma 3,865.00 -3.00 -0.08% -5.01%
Acadia Pharmaceuticals 16.86 0.26 1.54% -2.23%
AcelRx Pharmaceuticals 0.32 0.01 3.93% -66.02%
Aerie Pharmaceuticals 11.64 -0.10 -0.85% -20.22%
Cara Therapeutics 11.28 -0.47 -4.00% -11.32%
Depomed 3.68 -0.02 -0.54% 292.41%
Endo International 0.37 -0.004 -1.18% -90.21%
Halozyme Therapeutics 44.63 1.54 3.57% 9.60%
Horizon Pharma 64.17 -0.73 -1.12% -39.16%
Jazz Pharmaceuticals 158.50 -1.76 -1.10% 14.97%
J&J 167.57 1.48 0.89% -6.63%
Neurocrine Biosciences 106.64 -0.76 -0.70% 16.15%
Pacira 57.97 0.24 0.42% 0.50%
Pfizer 49.86 0.11 0.22% -1.11%
Cassava Sciences Inc. 20.21 0.02 0.10% -80.68%
RedHill Biopharma 0.98 -0.06 -5.35% -85.75%
Revance Therapeutics 22.34 0.22 0.97% -13.96%
Supernus Pharmaceuticals 33.97 -0.03 -0.07% 37.90%
Teva Pharmaceutical Industries 11.06 -0.14 -1.25% 16.67%
Vanda Pharmaceuticals 10.45 -0.04 -0.38% -36.28%

Indexes Price Day Year
USND 13103 -23.93 -0.18% -10.60%
US2000 2021 -2.12 -0.10% -7.19%

Cara Therapeutics
Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The Company is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The Company is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates.